ARMELLE PHALIPON

Armelle Phalipon is a microbiologist leading a group within the Molecular Microbial Pathogenesis Unit, INSERM U786, at the Institut Pasteur, Paris, France. Working in the field of diarrheal diseases, her team is interested in deciphering the cross-talks between enteropathogenic bacteria and the host immune system. The main current studies aim at deciphering how Shigella, the bacterium responsible for bacillary dysentery, impacts on the development of the short-term, poorly effective protective immunity elicited in response to infection. Armelle Phalipon has a long-standing interest in combining fundamental and applied research. Indeed, in collaboration with Dr. Laurence Mulard (Institut Pasteur, Paris), she has designed a new type of Shigella vaccine candidate that will enter a phase 1 clinical trial in 2016 for proof of concept in humans. She is co-founder and co-director with Frédéric Tangy of the first International Vaccinology Course launched at the Pasteur Institute in 2008.

FRÉDÉRIC TANGY

Frédéric Tangy, PhD, Dr.Sc., Director of Research at CNRS, is the head of the Viral Genomics and Vaccination Research Unit at Institut Pasteur, Paris (CNRS UMR-3569). After his PhD in 1980 and his Dr. Sc. in 1984 at Paris VI University he made his career as a virologist first at CNRS then at Institut Pasteur. He is co-director of the international Vaccinology course of Institut Pasteur, vice-president of the Scientific Council of Institut Pasteur, and member of ASM, ESGT, IAS, SFI. He is the author of 110 publications in international scientific journals and 19 international patents. In the recent years, he has developed two research programs: 1) generation of polyvalent viral attenuated vaccines based on a vector derived from measles vaccine. This project extends from the design of antigens and generation of recombinant vectors, to preclinical and clinical development in the field of HIV, dengue, chikungunya and malaria vaccines. 2) The second project investigates the interactions between viral and host proteins in a systematic way using functional genomic approaches such as high-throughput cloning, yeast two-hybrid, deep sequencing and high-throughput drug screening. This project aims at understanding at a molecular level the interactions between viral and host proteins and RNA in the field of paramyxoviruses. These observations lead to identify new drug targets and new determinants of pathogenicity/attenuation.

WITH THE PARTICIPATION OF / AVEC LA PARTICIPATION DE :

Richard ASPINALL DSc FRCP(Edin) FRCPath Academy of Health and Wellbeing, Anglia Ruskin university

Deborah ATHERLY, Director, Health Economics and Outcomes Research PATH, Seattle USA

Brigitte AUTRAN, CIMI (Centre de recherches Immunologie & Maladies Infectieuses) Université Pierre et Marie Curie Hôpital Pitié-Salpétrière Paris France

Michel BEURRET, Scientific Director Bacterial Processes & Analytics, Janssen

Maria Elena BOTTAZZI, PhD FASTMH, Associate Dean National School of Tropical Medicine Baylor College of Medicine Houston, TX USA

Stephen BROWN PhD, Executive Director BE Vaccines, Nantes, France

Joël CALMET, Sanofi Pasteur

Diana CHANG BLANC, World Health Organization Expanded Programme on Immunization Programme Operations Team Manager

Behazine COMBADIERE, Director of Research, Inserm, Centre d’Immunologie et des Maladies Infectieuses Cimi-Paris, France

Mark FLETCHER Senior Director, Pfizer, Paris

Giuseppe DEL GIUDICE, MD,PhD, GlaxoSmithKline, Research Center Siena, Italy

Francis DELPEYROUX, WHO Collaborative Centre of Research on Enteroviruses & Viral Vaccines. Biology of Enteric Viruses Unit. INSERM U994 – INSTITUT PASTEUR

Othmar G ENGELHARDT, Principal Scientist National Institute for Biological Standards and Control a centre of the Medicines and Healthcare products Regulatory Agency

Mark FLETCHER, Senior Director, Pfizer, Paris

Guido GRANDI, Prof. Microbiology and Clinical Microbiology, University of Trento, Trento, Italy

Marie-Lise GOUGEON, Antiviral Immunity, Biotherapy and Vaccine Unit Institut Pasteur

Nicole GUISO ,Molecular Prevention and Therapy of Human Diseases Research Unit French National Center of Reference for Pertussis and other bordetelloses and for toxinogenic corynebacteria Institut Pasteur, Paris, France

Karin HARDT, PhD, Director, Worldwide Vaccinology, Vaccine Education and Medical Training GSK Vaccines

Ruth A. KARRON, M.D., Professor and Director, Center for Immunization Research Bloomberg School of Public Health Johns Hopkins University

Daniel LÉVY-BRUHL, French Institute for Public Health Surveillance

David JM Lewis MD, Imperial College, London

Arnaud MARCHANT,Institute for Medical Immunology Université Libre de Bruxelles

Flor MUNOZ, MD, Associate Professor of Pediatrics Baylor College of Medicine Houston, Texas

Stanley PLOTKIN, Professor Emeritus of Pediatrics University of Pennsylvania

Audino PODDA, Vaccines Institute for Global Health GSK – Siena Italy

Rino RAPPUOLI, Coordinator of ADITEC European project and Chief Scientist, GSK Vaccines

Zarifah HUSSAIN REED CEO and Chief Medical Officer Vac4All

Rafick-Pierre SEKALY, Professeur Departement de Pathologie Case western Reserve University

Steffen STENGER, Medical Microbiology and Infection Control, University Hospital Ulm, Germany

Daniel TARANTOLA, MD, Former Director of the WHO Programme on Immunization, Vaccines and Biologicals WHO Headquarters, Geneva

Angus THOMSON, Director, Vaccination Advocacy, Sanofi Pasteur

Timo VESIKARI, Vaccine Research Center University of Tampere Finland

Peter J. WHITE, Public Health England and Imperial College London, UK